A 14-year-old boy from Maesteg, Ethan Griffiths, has been given renewed hope after his Burkitt Lymphoma aggressively returned just two weeks after he had celebrated the end of successful chemotherapy treatment. Ethan, who was diagnosed after emergency bowel surgery in January, had undergone six rounds of chemotherapy at Noah's Ark Children's Hospital before being declared cancer-free in May. His family described the two weeks following his remission as a period of "relative normality" before the pain returned.
The devastating news of the cancer's relapse came swiftly, with tests revealing aggressive regrowth and fluid build-up on his lungs, causing breathing difficulties. Burkitt Lymphoma is a rare, aggressive form of non-Hodgkin lymphoma, more prevalent in children and young adults. It is known for its rapid growth and can sometimes be resistant to initial treatments, making relapses particularly challenging to manage.
Ethan has now been accepted onto a clinical trial for a new type of treatment, offering a crucial lifeline. His father, Lloyd Griffiths, 56, stated that the trial, specifically for Burkitt Lymphoma relapses, presents a "fighting chance" for his son, with a reported 50% chance of success. This trial is being conducted across multiple UK centres, including Bristol Royal Hospital for Children, Birmingham, and Manchester, focusing on two targeted drugs for children and young people with B-cell non-Hodgkin lymphoma that has either not responded to standard treatment or has relapsed.
The new treatment, which Ethan commenced in Bristol, represents a significant development in the fight against aggressive childhood cancers. Clinical trials are vital for developing new therapies, especially for conditions like Burkitt Lymphoma where relapses can be particularly challenging. The family is resolute in their commitment, stating they will "do everything we can for our boy," including exploring international treatment options if the current trial is unsuccessful.
Burkitt Lymphoma accounts for approximately 1-2% of all non-Hodgkin lymphomas in the UK, but its incidence is higher in children. According to Cancer Research UK, around 6,000 cases of non-Hodgkin lymphoma are diagnosed each year in the UK, with a small percentage being Burkitt Lymphoma. While standard chemotherapy regimens are often effective, relapses can be difficult to treat, highlighting the critical need for advanced trial treatments like the one Ethan is now undertaking. For more information on lymphoma or to seek medical advice, individuals should contact their GP or NHS 111.